Functional Coronary Angiography Guided Revascularization in STEMI

Primary Efficacy Outcome: Patient Oriented Composite Outcome,Primary Safety Outcome: Major Bleeding and Contrast - Associated Acute Kidney Injury

The goal of this multicenter randomized clinical trial is to test the superiority in terms of
 efficacy of the Angiography-derived fractional flow reserve (AIR) over that based on
 conventional angiography (ANGIO) strategy in the management of non-culprit lesions in STEMI
 patients with multivessel disease.
 
 The main questions it aims to answer are:
 
 - is an Angiography-derived fractional flow reserve strategy superior to a conventional
 angiography strategy in reducing the occurrence of the composite efficacy endpoint of
 all-cause death, myocardial infarction, cerebrovascular accident, or ischemia-driven
 revascularization.
 
 - is an Angiography-derived fractional flow reserve strategy superior to a conventional
 angiography strategy in reducing the occurrence of the composite safety endpoint of of
 contrast-associated acute kidney injury and Bleeding Academic Research Consortium (BARC)
 type 3-5.
 
 Participants will be randomized after the successful treatment of the culprit lesion to one
 of the two strategies and prospectively followed-up.